IAC/Interactivecorp vs Twist Bioscience Corp — how do they compare? IAC/Interactivecorp trades at $40.94 (market cap $3.05B), while Twist Bioscience Corp trades at $155.24 (market cap $10.08B). The key difference: Twist Bioscience Corp is far larger — about 3.3× IAC/Interactivecorp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, IAC/Interactivecorp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IAC/Interactivecorp for 79 Days and Twist Bioscience Corp for 27 Days on average.
| PPLI | TWST | |
|---|---|---|
Market Cap | $3.05B | $10.08B |
Volume | 931,019 | 4,229,037 |
Sector | Media | Health |
52-Week High | $47.62 | $205.00 |
52-Week Low | $31.52 | $25.45 |
Typical Hold Time | 79 Days | 27 Days |
Enterprise Value | $3.53B | $10.01B |
Signals from Pluang's Aura AI — not financial advice
PPLI trades at $40.59, down 1.7% in the past 24 hours, with a bullish technical signal from moving averages. The stock shows mixed fundamentals: revenue declined to $2.39B in 2025 with a net loss of $104.03M, but valuation ratios appear attractive with a P/E of 6.87 and P/B of 0.59. Recent news highlights potential M&A activity, as MGM Resorts is reportedly considering a bid for PPLI, following PPLI's withdrawal of its own offer to buy MGM.
The outlook is cautiously optimistic, supported by strong analyst consensus (71.4% buy ratings) and potential upside from strategic deals. Key risks include inconsistent profitability, high debt levels, and execution challenges in a competitive media landscape. Earnings volatility remains a concern, but the low valuation and M&A speculation provide catalysts for investor interest.
TWST trades at $155.65, down 6.78% today, reflecting a bearish technical signal and recent earnings misses. Revenue growth is strong, rising to $376.57M in 2025, but profitability remains elusive with a net income margin of -31.66%. The company's partnership with Lilly TuneLab for AI-driven drug discovery has generated positive news flow, yet cash flow remains negative, and the stock trades at elevated valuation multiples like P/S of 22.01.
The outlook is mixed: strong analyst buy-side consensus (73% Buy) and strategic AI partnerships offer growth potential, but persistent losses, high cash burn, and bearish technicals pose significant risks. Investors face a trade-off between long-term innovation prospects and near-term financial instability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
Read more on PPLI →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →